A single but durable stable disease sends the microcap's stock up 730%.

MK-8294 starts phase 1, but its mechanism is anybody's guess.

A newly published cache of CRLs includes six novel oncology drugs.

The deal for ISB 2001 is worth $700m up front.

Autogene cevumeran goes on hold in adjuvant bladder cancer.

Weeks after criticising the group’s big pharma partner, John Houston is on his way out.

ESO-T01 delivers its first four multiple myeloma case reports.